Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.
Catherine S DiefenbachJessica CaroAkiko KoideMichael GrossbardJudith D GoldbergBruce RaphaelKenneth HymesTibor MoskovitsMaxim KreditorDavid KaminetzkyShella Saint Fleur-LominyJun ChoiSara A ThannickalKenneth A StaplefordShohei KoidePublished in: medRxiv : the preprint server for health sciences (2021)
Non Hodgkin lymphoma (NHL) and Chronic Lymphocytic leukemia (CLL) patients who are treated with anti-CD20 antibody therapy, BTK inhibitor therapy, or who are monitored with active disease, have decreased antibody response to SARS-CoV-2 vaccination and decreased antibody titers compared to healthy controls. Antibody titers do not boost following second vaccination, and very few patients generate neutralizing antibodies against SARS-CoV-2. This data is of particular importance, given the recent guidance from the CDC that vaccinated patients no longer need to be masked indoors as well as outdoors. Patients with NHL or CLL who fall into these categories should not consider their immunity from vaccination to be assured. If infected with SARS-CoV-2, they should be a high priority for monoclonal antibody directed therapy. Unless immune response to vaccination is confirmed with laboratory testing, they should continue to mask, socially distance, and to avoid close contact with non-vaccinated individuals.
Keyphrases
- sars cov
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- chronic lymphocytic leukemia
- peritoneal dialysis
- prognostic factors
- immune response
- respiratory syndrome coronavirus
- obstructive sleep apnea
- zika virus
- patient reported
- machine learning
- electronic health record
- data analysis
- replacement therapy